An analysis based on datasets from four studies of memory and ageing reveals differences in the relationship of cognition with cerebrospinal fluid, but not imaging, biomarkers for Alzheimer disease between self-identified Black and White participants. These findings highlight the importance of precision medicine to address Alzheimer disease disparities across diverse populations.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 19, 1598–1695 (2023).
Iwatsubo, T., Irizarry, M. C., Lewcock, J. W. & Carrillo, M. C. Alzheimer’s targeted treatments: focus on amyloid and inflammation. J. Neurosci. 43, 7894–7898 (2023).
Jack, C. R. Jr et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).
Hansson, O. et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement. 18, 2669–2686 (2022).
Bonomi, S. et al. Relationships of cognitive measures with cerebrospinal fluid but not imaging biomarkers of Alzheimer disease vary between Black and White individuals. Ann. Neurol. https://doi.org/10.1002/ana.26838 (2023).
Morris, J. C. et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol. 76, 264–273 (2019).
Deters, K. D. et al. Amyloid PET imaging in self-identified non-Hispanic Black participants of the Anti-Amyloid in Asymptomatic Alzheimer’s Disease (A4) study. Neurology 96, e1491–e1500 (2021).
Wilkins, C. H. et al. Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) cohort study. JAMA Neurol. 79, 1139–1147 (2022).
Schindler, S. E. et al. Effect of race on prediction of brain amyloidosis by plasma Aβ42/Aβ40, phosphorylated tau, and neurofilament light. Neurology 99, e245–e257 (2022).
Windon, C. et al. IDEAS and New IDEAS: amyloid PET in diverse populations. Alzheimers Dement. 17, e051946 (2021).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carrillo, M.C., Mahinrad, S. Navigating complexities of racial disparities in Alzheimer disease biomarkers. Nat Rev Neurol 20, 205–206 (2024). https://doi.org/10.1038/s41582-024-00930-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-024-00930-6
